Disease-modifying therapies and infectious risks in multiple sclerosis

Nature Reviews Neurology

Volumn 12, Issue 4, 2016, Pages 217-233

  Winkelmann, Alexander ^a   Loebermann, Micha ^a   Reisinger, Emil C ^a   Hartung, Hans Peter ^b   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; DACLIZUMAB; DEXAMETHASONE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; GLUCOCORTICOID; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABSCESS; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; APPENDICITIS; BACTERIAL INFECTION; BRONCHITIS; CANDIDIASIS; CELLULITIS; CONTROLLED CLINICAL TRIAL (TOPIC); CRYPTOCOCCAL MENINGITIS; CRYPTOSPORIDIOSIS; DIARRHEA; DISEASE CONTROL; DISEASE MODIFYING TREATMENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOMETRITIS; ENTERITIS; FLU LIKE SYNDROME; FURUNCULOSIS; GASTROENTERITIS; HEMIPARESIS; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; IMMUNOTHERAPY; INFECTION; INFECTION RISK; INFLUENZA; LEUKOCYTOSIS; LEUKOPENIA; LISTERIOSIS; LUNG TUBERCULOSIS; LYMPHOCYTOPENIA; MENINGOENCEPHALITIS; MULTIPLE SCLEROSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; PARASITOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYELONEPHRITIS; RELAPSE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEIZURE; SEPTICEMIA; SINUSITIS; TONSILLITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; VAGINA CANDIDIASIS; VIRUS INFECTION; VISUAL DISORDER; ANIMAL; CHEMICALLY INDUCED; COMMUNICABLE DISEASES; COMPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMMUNICABLE DISEASES; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; RISK FACTORS;

EID: 84960193186     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.21     Document Type: Review

References (255)

1. Lassmann, H. Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 333, 1-4 (2013).
2. Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188-2197 (2011).
3. Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183-193 (2015).
4. Lassmann, H. Spinal cord pathology in multiple sclerosis. Lancet Neurol. 14, 348-349 (2015).
5. Zettl, U. K., Stuve, O. & Patejdl, R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun. Rev. 11, 167-173 (2012).
6. Broadley, S. A. et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists. J. Clin. Neurosci. 21, 1857-1865 (2014).
7. Correale, J. et al. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. J. Neurol. Sci. 339, 196-206 (2014).
8. Freedman, M. S. et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can. J. Neurol. Sci. 40, 307-323 (2013).
9. Aktas, O., Kieseier, B. & Hartung, H. P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 33, 140-152 (2010).
10. Jeffery, D. R. Recent advances in treating multiple sclerosis: efficacy, risks and place in therapy. Ther. Adv. Chron. Dis. 4, 45-51 (2013).
11. Killestein, J., Rudick, R. A. & Polman, C. H. Oral treatment for multiple sclerosis. Lancet Neurol. 10, 1026-1034 (2011).
12. Meuth, S. G., Gobel, K. & Wiendl, H. Immune therapy of multiple sclerosis - future strategies. Curr. Pharm. Des. 18, 4489-4497 (2012).
13. Mulakayala, N., Rao, P., Iqbal, J., Bandichhor, R. & Oruganti, S. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview. Eur. J. Med. Chem. 60, 170-186 (2013).
14. Abinun, M. An overview of infectious complications in children on new biologic response-modifying agents. Pediatr. Health 4, 509-517 (2010).
15. Afif, W. & Loftus Jr, E. V. Safety profile of IBD therapeutics: infectious risks. Gastroenterol. Clin. North Am. 38, 691-709 (2009).
16. Breda, L., Del Torto, M., De Sanctis, S. & Chiarelli, F. Biologics in children's autoimmune disorders: efficacy and safety. Eur. J. Pediatr. 170, 157-167 (2011).
17. Berger, J. R. & Houff, S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 65, 367-377 (2009).
18. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
19. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
20. Gold, R. et al. Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098-1107 (2012).
21. Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
22. McDonald, W. I. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121-127 (2001).
23. Pirko, I. & Rodriguez, M. Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial. Arch. Neurol. 61, 1148-1149 (2004).
24. Goodkin, D. E. et al. A Phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51, 239-245 (1998).
25. Chinen, J. & Shearer, W. T. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 125, S195-S203 (2010).
26. Schweingruber, N., Reichardt, S. D., Luhder, F. & Reichardt, H. M. Mechanisms of glucocorticoids in the control of neuroinflammation. J. Neuroendocrinol. 24, 174-182 (2012).
27. Rommer, P. S. et al. Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis - an observational study. Eur. J. Clin. Invest. 45, 587-593 (2015).
28. Klein, N. C., Go, C. H. & Cunha, B. A. Infections associated with steroid use. Infect. Dis. Clin. North Am. 15, 423-432 (2001).
29. Dixon, W. G., Suissa, S. & Hudson, M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res. Ther. 13, R139 (2011).
30. Le Page, E. et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 386, 974-981 (2015).
31. Stahn, C., Lowenberg, M., Hommes, D. W. & Buttgereit, F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol. 275, 71-78 (2007).
32. Spies, C. M., Bijlsma, J. W., Burmester, G. R. & Buttgereit, F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr. Opin. Pharmacol. 10, 302-307 (2010).
33. Weinshenker, B. G. et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46, 878-886 (1999).
34. Keegan, M. et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366, 579-582 (2005).
35. Multiple Sclerosis Therapy Consensus Group et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J. Neurol. 255, 1449-1463 (2008).
36. Ehler, J. et al. Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome. Ther. Apher. Dial. 18, 489-496 (2014).
37. Ehler, J. et al. Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: a retrospective analysis of 90 patients. PLoS ONE 10, e0134583 (2015).
38. Lehmann, H. C., Hartung, H. P., Hetzel, G. R., Stuve, O. & Kieseier, B. C. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch. Neurol. 63, 930-935 (2006).
39. Wing, E. J., Bruns, F. J., Fraley, D. S., Segel, D. P. & Adler, S. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 244, 2423-2426 (1980).
40. Mokrzycki, M. H. & Kaplan, A. A. Therapeutic plasma exchange: complications and management. Am. J. Kidney Dis. 23, 817-827 (1994).
41. Haugh, P. J., Levy, C. S., Smith, M. A. & Walshe, D. K. Nosocomial Neisseria meningitidis sepsis as a complication of plasmapheresis. Clin. Infect. Dis. 22, 1116-1117 (1996).
42. Vucic, S. & Davies, L. Safety of plasmapheresis in the treatment of neurological disease. Aust. N. Z. J. Med. 28, 301-305 (1998).
43. Kaneko, S. et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Hepatol. Res. 40, 1072-1081 (2010).
44. Lin, J. H. et al. Prognostic factors and complication rates for double-filtration plasmapheresis in patients with Guillain-Barré syndrome. Transfus. Apher. Sci. 52, 78-83 (2015).
45. Yeh, J. H., Chen, W. H. & Chiu, H. C. Complications of double-filtration plasmapheresis. Transfusion 44, 1621-1625 (2004).
46. Rodnitzky, R. L. & Goeken, J. A. Complications of plasma exchange in neurological patients. Arch. Neurol. 39, 350-354 (1982).
47. Bouget, J., Chevret, S., Chastang, C. & Raphael, J. C. Plasma exchange morbidity in Guillain-Barré syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group. Crit. Care Med. 21, 651-658 (1993).
48. Boucher, C. A., de Gans, J., van Oers, R., Danner, S. & Goudsmit, J. Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré syndrome. Clin. Neurol. Neurosurg. 90, 235-236 (1988).
49. [No authors listed.] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993).
50. Ebers, C. G. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/ remitting multiple sclerosis. Lancet 352, 1498-1504 (1998).
51. Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39, 285-294 (1996).
52. Calabresi, P. A. et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, Phase 3, double-blind study. Lancet Neurol. 13, 657-665 (2014).
53. Kieseier, B. C. et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult. Scler. 21, 1025-1035 (2014).
54. Lehmann, H. C., Kruger, K., Fink, G. R. & Schroeter, M. Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. J. Neurol. 262, 771-773 (2015).
55. McGlasson, S., Jury, A., Jackson, A. & Hunt, D. Type I interferon dysregulation and neurological disease. Nat. Rev. Neurol. 11, 515-523 (2015).
56. Johnson, K. P. et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
57. Khan, O., Rieckmann, P., Boyko, A., Selmaj, K. & Zivadinov, R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann. Neurol. 73, 705-713 (2013).
58. US Food and Drug Administration. Full prescribing information for copaxone (glatiramer acetate). FDA.gov [online], http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/020622s057lbl.pdf (2009).
59. Aktas, O., Kury, P., Kieseier, B. & Hartung, H. P. Fingolimod is a potential novel therapy for multiple sclerosis. Nat. Rev. Neurol. 6, 373-382 (2010).
60. Kappos, L. et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult. Scler. Relat. Disord. 3, 494-504 (2014).
61. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
62. Arvin, A. M. et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMANeurol. 72, 31-39 (2015).
63. Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H. P. & Zettl, U. K. Fingolimod treatment for multiple sclerosis patients. What do we do with varicella? Ann. Neurol. 70, 673-674; author reply 674 (2011).
64. Issa, N. P. & Hentati, A. VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 84, 99-100 (2015).
65. Pfender, N., Jelcic, I., Linnebank, M., Schwarz, U. & Martin, R. Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis. Neurology 84, 2377-2378 (2015).
66. Huang, D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology 85, 1001-1003 (2015).
67. Achtnichts, L., Obreja, O., Conen, A., Fux, C. A. & Nedeltchev, K. Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 72, 1203-1205 (2015).
68. Forrestel, A. K., Modi, B. G., Longworth, S., Wilck, M. B. & Micheletti, R. G. Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. http:// dx.doi.org/10.1001/jamaneurol.2015.4259 (2016).
69. Wollebo, H. S., White, M. K., Gordon, J., Berger, J. R. & Khalili, K. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann. Neurol. 77, 560-570 (2015).
70. [No authors listed.] Dear Doctor letter (rote-hand-brief) on Gilenya® (fingolimod): first reported case of progressive multifocal leukoencephalopathy (PML). Federal Institute for Drugs and Medical Devices [online], http://www.bfarm.de/SharedDocs/ Risikoinformationen/Pharmakovigilanz/ EN/RHB/2015/rhb-gilenya.pdf;jsessionid= 68F44C260AEBC569F0AA830A9C796DE3.1- cid350?-blob=publicationFile&v=4 (in German) (2015).
71. [No authors listed.] Fingolimod. Kompetenznetz Multiple Sklerose [online], http://www.kompetenznetz-multiplesklerose.de/images/stories/PDF-Dateien/ kknms-handbuch-fty720-2015-frei.pdf (in German) (2015).
72. Fox, R. J. et al. Placebo-controlled Phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087-1097 (2012).
73. [No authors listed.] Tecfidera. European Medicines Agency [online], http://www.ema.europa.eu/docs/en- GB/document-library/Summary-of-opinion-Initial- authorisation/human/002601/WC500140695.pdf (2013).
74. US Food and Drug Administration. FDA approves new multiple sclerosis treatment: Tecfidera. FDA.gov [online], http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm345528.htm (2013).
75. Khatri, B. O. et al. The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult. Scler. Relat. Disord. 4, 377-379 (2015).
76. Spencer, C. M., Crabtree-Hartman, E. C., Lehmann-Horn, K., Cree, B. A. & Zamvil, S. S. Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol. Neuroimmunol. Neuroinflamm. 2, e76 (2015).
77. Rosenkranz, T., Novas, M. & Terborg, C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 372, 1476-1478 (2015).
78. [No authors listed.] Tecfidera® (dimethyl fumarate): new measures to minimise the risk of PML - enhanced monitoring and stopping rules. Biogen [online], https://assets.digital.cabinet-office. gov.uk/media/566ad4c2e5274a105e00001d/ Tecfidera-UK-DHPC-FINAL-25-Nov-2015.pdf (2015).
79. [No authors listed.] Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. European Medicines Agency [online], http:// www.ema.europa.eu/docs/en-GB/document-library/ Press-release/2015/10/WC500196017.pdf (2015).
80. Ermis, U., Weis, J. & Schulz, J. B. PML in a patient treated with fumaric acid. N. Engl. J. Med. 368, 1657-1658 (2013).
81. van Oosten, B. W., Killestein, J., Barkhof, F., Polman, C. H. & Wattjes, M. P. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N. Engl. J. Med. 368, 1658-1659 (2013).
82. Sweetser, M. T., Dawson, K. T. & Bozic, C. Manufacturer's response to case reports of PML. N. Engl. J. Med. 368, 1659-1661 (2013).
83. Stoppe, M. et al. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J. Neurol. 261, 1021-1024 (2014).
84. Nieuwkamp, D. J. et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N. Engl. J. Med. 372, 1474-1476 (2015).
85. Bartsch, T. et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann. Neurol. 78, 501-514 (2015).
86. Dammeier, N., Schubert, V., Hauser, T. K., Bornemann, A. & Bischof, F. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol. 15, 108 (2015).
87. [No authors listed.] Arzneimittelkommission der deutschen Ärzteschaft-"Aus der UAW-Datenbank": Reversibles Kaposi-Sarkom unter Fumaderm®-assoziierter Lymphozytopenie. Dtsch. Arztebl. Int. 106, 2380 (in German) (2009).
88. [No authors listed.] Arzneimittelkommission der Deutschen Ärzteschaft: "Aus der UAW-Datenbank"-Nokardiose bei Lymphopenie durch Fumaderm®. Dtsch. Arztebl. Int. 110, 1220-1221 (in German) (2013).
89. Reich, K., Hartung, H. P. & Lebwohl, M. More on PML in patients treated with dimethyl fumarate. N. Engl. J. Med. 374, 294-295 (2016).
90. Gheuens, S., Pierone, G., Peeters, P. & Koralnik, I. J. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J. Neurol. Neurosurg. Psychiatry 81, 247-254 (2010).
91. O'Connor, P. et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 365, 1293-1303 (2011).
92. Confavreux, C. et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Neurol. 13, 247-256 (2014).
93. [No authors listed.] Aubagio. European Medicines Agency [online], http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002514/WC500140690.pdf (2013).
94. O'Connor, P. W. et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006).
95. Confavreux, C. et al. Long-term follow-up of a Phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult. Scler. 18, 1278-1289 (2012).
96. Miller, A. E. et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Neurol. 13, 977-986 (2014).
97. Filippini, G. et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst. Rev. 6, CD008933 (2013).
98. Casetta, I., Iuliano, G. & Filippini, G. Azathioprine for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD003982 (2007).
99. Yudkin, P. L. et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 338, 1051-1055 (1991).
100. US Food and Drug Administration. IMURAN (azathioprine). FDA.gov [online], http:// www.accessdata.fda.gov/drugsatfda-docs/ label/2014/016324s037,017391s016lbl.pdf (2014).
101. Min, M. X., Weinberg, D. I. & McCabe, R. P. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. J. Clin. Pharm. Ther. 39, 107-111 (2014).
102. Yang, S. K. et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46, 1017-1020 (2014).
103. Rudick, R. A. et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911-923 (2006).
104. Valenzuela, R. M., Pula, J. H., Garwacki, D., Cotter, J. & Kattah, J. C. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J. Neurol. Sci. 340, 109-111 (2014).
105. US Food and Drug Administration. TYSABRI (natalizumab) injection for intravenous use. FDA.gov [online], http://www.accessdata.fda.gov/drugsatfda- docs/label/2008/125104s033lbl.pdf (2008).
106. Warnke, C., Olsson, T. & Hartung, H. P. PML: the dark side of immunotherapy in multiple sclerosis. Trends Pharmacol. Sci. 36, 799-801 (2015).
107. Van Assche, G. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
108. Sorensen, P. S. et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult. Scler. 18, 143-152 (2012).
109. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880 (2012).
110. Monaco, M. C. & Major, E. O. Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors. Front. Immunol. 6, 159 (2015).
111. Berger, J. R. & Fox, R. J. Reassessing the risk of natalizumab-associated PML. J. Neurovirol. http:// dx.doi.org/10.1007/s13365-016-0427-6 (2016).
112. McGuigan, C. et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J. Neurol. Neurosurg. Psychiatry 87, 117-125 (2016).
113. Warnke, C. et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch. Neurol. 67, 923-930 (2010).
114. Clifford, D. B. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 9, 438-446 (2010).
115. [No authors listed.] Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri. European Medicines Agency [online], http:// www.ema.europa.eu/docs/en-GB/document-library/ Referrals-document/Tysabri-20/Recommendation- provided-by-Pharmacovigilance-Risk-Assessment- Committee/WC500201887.pdf (2016).
116. Warnke, C. et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 792-801 (2014).
117. Wattjes, M. P. & Warnke, C. Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good? J. Neurol. Neurosurg. Psychiatry 87, 115 (2015).
118. Plavina, T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802-812 (2014).
119. Gheuens, S. et al. Progressive multifocal leukoencephalopathy not observed later than 6 months after natalizumab discontinuation (Poster). Presented at the 67th American Academy of Neurology Annual Meeting (2015).
120. Fine, A. J., Sorbello, A., Kortepeter, C. & Scarazzini, L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann. Neurol. 75, 108-115 (2014).
121. Wattjes, M. P. & Killestein, J. Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true? Ann. Neurol. 75, 462 (2014).
122. Cox, A. L. et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35, 3332-3342 (2005).
123. Jones, J. L. et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052-2061 (2009).
124. Thompson, S. A., Jones, J. L., Cox, A. L., Compston, D. A. & Coles, A. J. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 30, 99-105 (2010).
125. The CAMMS223 Trial Investigators. Alemtuzumab versus interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
126. Cohen, J. A. et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet 380, 1819-1828 (2012).
127. Coles, A. J. et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase 3 trial. Lancet 380, 1829-1839 (2012).
128. Menge, T., Stuve, O., Kieseier, B. C. & Hartung, H. P. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 83, 87-97 (2014).
129. Hartung, H. P., Aktas, O. & Boyko, A. N. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult. Scler. 21, 22-34 (2015).
130. Havrdova, E., Horakova, D. & Kovarova, I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther. Adv. Neurol. Disord. 8, 31-45 (2015).
131. Waggoner, J., Martinu, T. & Palmer, S. M. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J. Heart Lung Transplant. 28, 395-398 (2009).
132. Isidoro, L., Pires, P., Rito, L. & Cordeiro, G. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. http://dx.doi.org/ 10.1136/bcr-2013-201781 (2014).
133. Tuohy, O. et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J. Neurol. Neurosurg. Psychiatry 86, 208-215 (2015).
134. Willis, M. D. et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult. Scler. http://dx.doi.org/ 10.1177/1352458515614092 (2015).
135. Wray, S. A descriptive analysis of infectious adverse events in alemtuzumab treated multiple sclerosis patients. Presented at the 25th Congress of the European Committee for the Treatment and Research In Multiple Sclerosis (2009).
136. Rau, D. et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis - report of two cases. Int. J. Mol. Sci. 16, 14669-14676 (2015).
137. Committee on Infectious Diseases & Committee on Nutrition & American Academy of Pediatrics. Consumption of raw or unpasteurized milk and milk products by pregnant women and children. Pediatrics 133, 175-179 (2014).
138. Hartung, H. P. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018-2025 (2002).
139. US Food and Drug Administration. NOVANTRONE. FDA.gov [online], http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/019297s030s031lbl.pdf (2008).
140. Martinelli Boneschi, F., Vacchi, L., Rovaris, M., Capra, R. & Comi, G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst. Rev. 5, CD002127 (2013).
141. Lutterotti, A. & Martin, R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol. 7, 538-547 (2008).
142. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
143. He, D. et al. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 12, CD009130 (2013).
144. Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460-471 (2009).
145. Rommer, P. S. et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). J. Neuroimmune Pharmacol. 11, 1-8 (2016).
146. Martin, S. T., Cardwell, S. M., Nailor, M. D. & Gabardi, S. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am. J. Transplant. 14, 788-796 (2014).
147. Lanini, S. et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 9, 36 (2011).
148. Carbone, J., del Pozo, N., Gallego, A. & Sarmiento, E. Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev. Anti Infect. Ther. 9, 405-413 (2011).
149. Dang, L., Dang, X., Koralnik, I. J. & Todd, P. K. JC polyomavirus granule cell neuronopathy in a patient treated with rituximab. JAMA Neurol. 71, 487-489 (2014).
150. Carson, K. R. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113, 4834-4840 (2009).
151. Tony, H. P. et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res. Ther. 13, R75 (2011).
152. Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 64, 3043-3051 (2012).
153. van Vollenhoven, R. F. et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 72, 1496-1502 (2013).
154. US National Library of Science. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01247324?term=NCT01247324&rank=1 (2016).
155. US National Library of Science. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01194570?term=NCT01194570&rank=1 (2016).
156. US National Library of Science. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01412333?term=NCT01412333&rank=1 (2016).
157. Kappos, L. et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378, 1779-1787 (2011).
158. Hauser, S. et al. Efficacy and safety of ocrelizumab in relapsing multiple sklerosis - results of the Phase III double-blind, interferon beta-1a controlled OPERA I and II studies. ECTRIMS Online Library [online], http://onlinelibrary.ectrims-congress.eu/ ectrims/2015/31st/116634/stephen.hauser.efficacy. and.safety.of.ocrelizumab.in.relapsing.multiple. html?f=m3 (2015).
159. Montalban, X. et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the Phase III, double-blind, placebo controlled ORATORIO study. ECTRIMS Online Library [online], http://onlinelibrary.ectrims-congress.eu/ ectrims/2015/31st/116701/xavier.montalban.efficacy. and.safety.of.ocrelizumab.in.primary.progressive. html?f=m3 (2015).
160. Emery, P. et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab Phase III program. PLoS ONE 9, e87379 (2014).
161. Sorensen, P. S. et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a Phase 2 study. Neurology 82, 573-581 (2014).
162. Wynn, D. et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 9, 381-390 (2010).
163. Gold, R. et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 381, 2167-2175 (2013).
164. Pfender, N. & Martin, R. Daclizumab (anti-CD25) in multiple sclerosis. Exp. Neurol. 262 Pt A, 44-51 (2014).
165. Kappos, L. et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 373, 1418-1428 (2015).
166. Loebermann, M. et al. Vaccination against infection in patients with multiple sclerosis. Nat. Rev. Neurol. 8, 143-151 (2011).
167. Russo, M. V. & McGavern, D. B. Immune surveillance of the CNS following infection and injury. Trends Immunol. 36, 637-650 (2015).
168. Dong-Si, T. et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann. Clin. Transl. Neurol. 1, 755-764 (2014).
169. Dong-Si, T. et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J. Neurovirol. 21, 637-644 (2015).
170. Baldwin, K. J. & Hogg, J. P. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr. Opin. Neurol. 26, 318-323 (2013).
171. Wattjes, M. P. & Barkhof, F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr. Opin. Neurol. 27, 260-270 (2014).
172. Wattjes, M. P. et al. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Mult. Scler. http://dx.doi.org/ 10.1177/1352458515615225 (2015).
173. Chahin, S. & Berger, J. R. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J. Neurovirol. 21, 623-631 (2015).
174. Clifford, D. B. Neurological immune reconstitution inflammatory response: riding the tide of immune recovery. Curr. Opin. Neurol. 28, 295-301 (2015).
175. Brickelmaier, M. et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother. 53, 1840-1849 (2009).
176. Elphick, G. F. et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306, 1380-1383 (2004).
177. Cettomai, D. & McArthur, J. C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch. Neurol. 66, 255-258 (2009).
178. Schroder, A. et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch. Neurol. 67, 1391-1394 (2010).
179. Alstadhaug, K. B. et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol. 71, 1030-1035 (2014).
180. Berger, B. et al. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. J. Neuroimmunol. 282, 118-122 (2015).
181. Buttgereit, F., Burmester, G. R., Straub, R. H., Seibel, M. J. & Zhou, H. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 63, 1-9 (2011).
182. Buttgereit, F. A fresh look at glucocorticoids. How to use an old ally more effectively. Bull. NYU Hosp. Jt Dis. 70 (Suppl. 1), 26-29 (2012).
183. Lehmann, H. C. & Hartung, H. P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J. Neuroimmunol. 231, 61-69 (2011).
184. Hu, X. et al. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. J. Clin. Pharmacol. 52, 798-808 (2012).
185. Caliceti, P. & Veronese, F. M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55, 1261-1277 (2003).
186. Fensterl, V. & Sen, G. C. Interferons and viral infections. Biofactors 35, 14-20 (2009).
187. Hundeshagen, A. et al. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J. Neuroinflamm. 9, 140 (2012).
188. Hecker, M. et al. Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment. Pharmacogenom. J. 12, 360 (2012).
189. Bongioanni, P., Lombardo, F., Moscato, G., Mosti, S. & Meucci, G. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis. Arch. Neurol. 56, 217-222 (1999).
190. Noronha, A., Toscas, A. & Jensen, M. A. Interferon beta augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27, 207-210 (1990).
191. Arnason, B. G. Interferon beta in multiple sclerosis. Clin. Immunol. Immunopathol. 81, 1-11 (1996).
192. Arnason, B. G. et al. Mechanisms of action of interferon-β in multiple sclerosis. Springer Semin. Immunopathol. 18, 125-148 (1996).
193. Ozenci, V., Kouwenhoven, M., Huang, Y. M., Kivisakk, P. & Link, H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-β)-and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-β) treatment. Clin. Exp. Immunol. 120, 147-153 (2000).
194. Shapiro, S., Galboiz, Y., Lahat, N., Kinarty, A. & Miller, A. The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β. J. Neuroimmunol. 144, 116-124 (2003).
195. Yushchenko, M. et al. Interferon-β-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J. Neurol. 250, 1224-1228 (2003).
196. Boster, A., Bartoszek, M. P., O'Connell, C., Pitt, D. & Racke, M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther. Adv. Neurol. Disord. 4, 319-332 (2011).
197. Ziemssen, T., Kumpfel, T., Klinkert, W. E., Neuhaus, O. & Hohlfeld, R. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125, 2381-2391 (2002).
198. Hong, J., Li, N., Zhang, X., Zheng, B. & Zhang, J. Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl Acad. Sci. USA 102, 6449-6454 (2005).
199. Teitelbaum, D., Milo, R., Arnon, R. & Sela, M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl Acad. Sci. USA 89, 137-141 (1992).
200. Fridkis-Hareli, M. & Strominger, J. L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160, 4386-4397 (1998).
201. O'Sullivan, C. & Dev, K. K. The structure and function of the S1P1 receptor. Trends Pharmacol. Sci. 34, 401-412 (2013).
202. Cohen, J. A. & Chun, J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 69, 759-777 (2011).
203. Chanvillard, C., Jacolik, R. F., Infante-Duarte, C. & Nayak, R. C. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front. Immunol. 4, 63 (2013).
204. Matloubian, M. et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004).
205. Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349 (2002).
206. Coelho, R. P., Payne, S. G., Bittman, R., Spiegel, S. & Sato-Bigbee, C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 323, 626-635 (2007).
207. Miron, V. E. et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am. J. Pathol. 176, 2682-2694 (2010).
208. Kohne, A. et al. Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Arch. Neurol. 69, 1280-1289 (2012).
209. Mullershausen, F. et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J. Neurochem. 102, 1151-1161 (2007).
210. Xie, J. H. et al. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J. Immunol. 170, 3662-3670 (2003).
211. Gold, R., Linker, R. A. & Stangel, M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin. Immunol. 142, 44-48 (2012).
212. Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678-692 (2011).
213. Scannevin, R. H. et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 341, 274-284 (2012).
214. Fox, R. I. et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin. Immunol. 93, 198-208 (1999).
215. Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J. & Wiendl, H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74, 659-674 (2014).
216. Elion, G. B. The George Hitchings and Gertrude Elion lecture. Ann. N. Y. Acad. Sci. 685, 400-407 (1993).
217. Rice, G. P., Hartung, H. P. & Calabresi, P. A. Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336-1342 (2005).
218. Leussink, V. I. et al. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol. 103, 131-136 (2002).
219. Wiendl, H. & Kieseier, B. Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. Nat. Rev. Neurol. 9, 125-126 (2013).
220. Xia, M. Q. et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J. 293, 633-640 (1993).
221. Koeller, J. & Eble, M. Mitoxantrone: a novel anthracycline derivative. Clin. Pharm. 7, 574-581 (1988).
222. Marriott, J. J. et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74, 1463-1470 (2010).
223. Burns, S. A. et al. Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Brain Res. 1473, 236-241 (2012).
224. Fidler, J. M., DeJoy, S. Q. & Gibbons, J. J. Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J. Immunol. 137, 727-732 (1986).
225. Riminton, D. S., Hartung, H. P. & Reddel, S. W. Managing the risks of immunosuppression. Curr. Opin. Neurol. 24, 217-223 (2011).
226. Winkelmann, A., Löbermann, M., Reisinger, E. C. & Zettl, U. K. Infektionen und Infektionsprävention bei Multipler Sklerose. Fragen und Antworten für die klinische Praxis. Nervenheilkunde 33, 883-890 (in German) (2014).
227. Winkelmann, A., Löbermann, M., Reisinger, E. C. & Zettl, U. K. Multiple sclerosis and infections. Akt. Neurol. 38, 339-350 (in German) (2011).
228. Frau, J. et al. Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. J. Neurol. Sci. 349, 249-250 (2015).
229. Chan, H. L., Ren, H., Chow, W. C., Wee, T. & Interferon Beta-1a Hepatitis C Study Group. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology 46, 315-323 (2007).
230. Eisenberg, M. et al. Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection. Antimicrob. Agents Chemother. 29, 122-126 (1986).
231. Mader, E. C. Jr et al. Tumefactive multiple sclerosis and hepatitis C virus 2a/2C infection: dual benefit of long-term interferon beta-1a therapy? J. Neurol. Sci. 349, 239-242 (2015).
232. Rao, H. Y. et al. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-β-1a with or without sustained viral response. Hepatogastroenterology 56, 328-334 (2009).
233. Tan, F. U., Cetinkaya, H., Erden, E., Ulkatan, S. & Aydin, N. Dual benefit from intramuscular interferon-β treatment in a patient with multiple sclerosis and chronic hepatitis-C virus infection. Hepatogastroenterology 49, 1686-1687 (2002).
234. Khouri, R. et al. IFN-β impairs superoxide-dependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. J. Immunol. 182, 2525-2531 (2009).
235. Maffione, A. B. et al. In vivo effects of recombinant-interferon-β1b treatment on polymorphonuclear cell and monocyte functions and on T-cell-mediated antibacterial activity in patients with relapsing-remitting multiple sclerosis. Immunopharmacol. Immunotoxicol. 22, 1-18 (2000).
236. Mattner, J. et al. Protection against progressive leishmaniasis by IFN-β. J. Immunol. 172, 7574-7582 (2004).
237. Olberg, H. K. et al. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult. Scler. 20, 1074-1080 (2014).
238. Smith, M. Y. et al. Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis. J. Manag. Care Spec. Pharm. 21, 650-660 (2015).
239. US Food and Drug Administration. FDA drug, safety communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs. FDA.gov [online], http://www.fda.gov/Drugs/DrugSafety/ucm456919. htm (2015).
240. Ermis, U., Weis, J. & Schulz, J. B. Case reports of PML in patients treated for psoriasis. N. Engl. J. Med. 369, 1081 (2013).
241. Comi, G. et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult. Scler. Relat. Disord. 5, 97-104 (2016).
242. Casetta, I., Iuliano, G. & Filippini, G. Azathioprine for multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80, 131-132; discussion 132 (2009).
243. Dahdaleh, D., Altmann, D. M., Malik, O. & Nicholas, R. S. Breathlessness, night sweats, and weight loss on natalizumab. Lancet 380, 726-727 (2012).
244. de Masson, A. et al. Cavitary pulmonary disease in a patient treated with natalizumab. Presse Med. 43, 1009-1012 (2014).
245. Hradilek, P., Zeman, D., Tudik, I., Zapletalova, O. & Ulmann, V. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis. Mult. Scler. 20, 639-640 (2014).
246. Kohlmann, R. et al. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis. Mult. Scler. 21, 1823-1832 (2015).
247. Kobeleva, X. et al. Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab. J. Neuroinflamm. 11, 19 (2014).
248. Kwiatkowski, A. et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult. Scler. 18, 909-911 (2012).
249. Sharma, K., Ballham, S. A., Inglis, K. E., Renowden, S. & Cottrell, D. A. Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion. Mult. Scler. Relat. Disord. 2, 385-387 (2013).
250. Shenoy, E. S., Mylonakis, E., Hurtado, R. M. & Venna, N. Natalizumab and HSV meningitis. J. Neurovirol. 17, 288-290 (2011).
251. Fine, A. J., Sorbello, A., Kortepeter, C. & Scarazzini, L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin. Infect. Dis. 57, 849-852 (2013).
252. Fragoso, Y. D., Brooks, J. B., Gomes, S., de Oliveira, F. T. & da Gama, P. D. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci. Ther. 19, 280-281 (2013).
253. Gutwinski, S. et al. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology 74, 521-523 (2010).
254. Zecca, C., Nessi, F., Bernasconi, E. & Gobbi, C. Ocular toxoplasmosis during natalizumab treatment. Neurology 73, 1418-1419 (2009).
255. Desoubeaux, G. et al. Two cases of opportunistic parasite infections in patients receiving alemtuzumab. J. Clin. Pathol. 65, 92-95 (2012).